Analysts/Institutional Investor Meet/Con. Call Updates

AI summary - Q2 FY27 consolidated sales INR161,000 million +11.8% y-y; EBITDA INR47,439 million +4.8% y-y; EBITDA margin 29.3%; adjusted net profit INR31,620 million - Global Innovative Medicines sales USD356 million +6.9%; Ilumya US psoriatic arthritis soft launch Nov 2026, full launch following months - India formulations sales INR55,523 million +17.3%; 15 new products launched; volume growth 6.7% - US business sales USD455 million -8.2% y-y due to lenalidomide erosion; 5 new generics launched - Emerging Markets sales USD350 million +7.6% constant currency; Rest of World USD241 million + y-y - R&D spend Q2 INR7,784 million (4.8% of sales), expected to ramp up in H2 FY27 - Organon acquisition on track to close Q4 FY27; acquisition costs in exceptional items - Multiple analyst queries on Ilumya US growth slowdown; management expects recovery over next few quarters - Net cash USD3.3 billion consolidated; effective tax rate 28.3% in Q2 FY27